Epidemiology and Biomarker Study in Alzheimer's Disease
← catalyst calendarNCT07142954 · readout ≤ 2,538 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
3,400estimated
Sites
4
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-25 | actual | When the study began enrolling |
| Primary completion | Jul 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer Disease
Intervention
- Other: P-tau217 Test
Primary outcome
what the primary-completion date above is the date OFTime to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite Components
measured Baseline up to 7 years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed